On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions.
CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) ... Read More
17
May2016
03
May2016
The Patented Medicine Prices Review Board (PMPRB) has released its April 2016 NEWSletter. Some recent changes include:
Public Consultation on PMPRB Framework Modernization
In December 2015, the PMPRB released its 2015-2018 Strategic Plan, the culmination of a year-long strategic planning process that identified a new vision, a revised mission statement, and four ... Read More
03
May2016
In June/July 2015, PDCI Market Access and H3 Consulting conducted an on-line survey to gauge the interest, experience and expectation surrounding private payer product listing agreements (PLAs). There was tremendous response to that survey with 27 individuals (19 from industry and 8 from the private insurer community) participating in the ... Read More
22
Apr2016
To meet the needs of Quebec’s Ministry of Health and Social Services (MSSS), the Institut national d’excellence en santé et en services sociaux (INESSS) has developed a new drug review process for stable blood products for their addition to the Liste des produits du système du sang du Québec.
In addition, ... Read More
19
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued the First Principles for Subsequent Entry Biologics (SEBs) to guide negotiations and inform expectations. These principles are now available on the pCPA website, found here.
The pCPA has also updated the status of negotiations on brand name drugs, included in ... Read More
11
Apr2016
On April 1, 2016, the pan-Canadian Pharmaceutical Alliance (pCPA) issued manufacturers a notification of first principles for subsequent entry biologics (SEBs) to guide negotiations and inform expectations. This information has not yet been posted on the pCPA website but is being shared with their permission.
Please see below for a copy ... Read More
30
Mar2016
Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective date of the following two CDR procedural revisions:
The timing of CDR review team’s responses being provided to the manufacturer, and
The revised CDR voluntary withdrawal procedure
The revised date for these two ... Read More
30
Mar2016
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs
In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert ... Read More
24
Mar2016
In December 2015, the Patented Medicine Prices Review Board (PMPRB) posted a Notice and Comment seeking stakeholder comments on the following proposed changes:
Reasonable Relationship Test (Schedule 4) Amendment
List Price relative to Maximum Average Potential Price (MAPP) Verification (Section C.11) Amendment
Subsequent to stakeholder feedback received during the public comment period, ... Read More
24
Mar2016
Effective April 1, 2016, all drug products reviewed by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) will no longer require a routine review by the Committee to Evaluate Drugs (CED), the Ontario Ministry of Health and Long-Term Care’s expert drug advisory committee. This change also ... Read More